Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer
Additional Chemotherapy Improves Survival in Women with Residual Disease After Neoadjuvant Chemotherapy
By
Phoebe Starr
Breast Cancer
May 2016, Vol 7, No 4
It is not clear how to treat residual disease after neoadjuvant therapy in patients with early HER2-negative breast cancer. Additional chemotherapy with capecitabine improved survival in this group of patients, according to a large Japanese study presented by lead investigator Masakazu Toi, MD, PhD, Professor, Breast Surgery, Kyoto Hospital, Japan, at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Omit Chemotherapy for Luminal A Breast Cancer?
By
Phoebe Starr
Breast Cancer
May 2016, Vol 7, No 4
Younger patients with luminal A subtype breast cancer may not need chemotherapy, according to a Danish trial presented by lead investigator Torsten O. Nielsen, MD, PhD, Professor, University of British Columbia, Vancouver, Canada, at the 2015 San Antonio Breast Cancer Symposium. Patients with luminal A biological subtype breast cancer have an excellent prognosis, even high-risk patients, the study suggests.
Read Article
Tamoxifen or Anastrozole for DCIS? Age and Symptoms Matter
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
Anastrozole and tamoxifen are similarly effective in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ (DCIS). The choice should depend on patient preferences, side-effect profiles, age, and other patient factors, according to 2 studies presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Survival Benefit for T-DM1 Confirmed in Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
The antibody-drug conjugate trastuzumab emtansine (T-DM1) improved overall survival (OS) compared with physician’s choice of therapy in patients with pretreated HER2-positive metastatic breast cancer, according to the final results of the phase 3 TH3RESA trial, which were presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
By
Laura Morgan
Breast Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Breast cancer is the leading cause of premature death in women. According to the American Cancer Society (ACS), more than 40,000 US women will die of breast cancer in 2015.
Read Article
Patients with Early Breast Cancer and Low Oncotype DX Scores Can Skip Chemotherapy
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
October 2015, Vol 6, No 9
Patients with early breast cancer and a low Onco
type
DX recurrence score can safely receive treatment with hormone therapy alone and avoid chemotherapy, according to results of the TAILORx trial, which was sponsored by the National Cancer Institute.
Read Article
80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection
By
Corbin Davis
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
November 2015, Vol 6, No 10
San Francisco, CA—A new genetic test may allow clinicians to improve their therapy decisions by better categorizing patients into specific subtypes compared with conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) subtyping. According to data presented at the 2015 Breast Cancer Symposium, the BluePrint 80-gene assay reclassifies approximately 23% of tumors, allowing for more effective therapy selection, particularly in patients with triple-positive (HER2-positive/hormone receptor–positive) disease.
Read Article
MRI Screening of Women at Average Risk for Breast Cancer Improves Detection
By
Corbin Davis
Breast Cancer
,
Cancer Screening
,
Personalized Medicine
November 2015, Vol 6, No 10
San Francisco, CA—Magnetic resonance imaging (MRI) screening of women who are at average risk for breast cancer had a mean additional cancer diagnosis yield of 15.8 per 1000 patients, surpassing the yields for digital breast tomosynthesis and ultrasound in a new study. The results were presented at the 2015 Breast Cancer Symposium, by Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH Aachen University, Germany. This suggests that breast MRI screening alone every 3 years may be sufficient for women at average risk.
Read Article
Controlled Ovarian Hyperstimulation Safe in Patients with Breast Cancer
By
Alice Goodman
Breast Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—Fertility preservation by controlled ovarian hyperstimulation with concurrent letrozole (Femara) is safe in women with breast cancer, according to a single-center, prospective study on the long-term safety of fertility preservation by the use of ovarian stimulation and concurrent aromatase inhibitors in women with breast cancer, presented at the 2015 Best of ASCO meeting in Boston. Controlled ovarian hyperstimulation had no impact on relapse-free survival and enabled live births in a substantial proportion of women who later chose to retrieve their frozen embryos or oocytes.
Read Article
More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
San Antonio, TX—Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA.
Read Article
Page 8 of 13
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma